Drug Profile
Peginterferon alfa-2a (Y-shaped pegylation) - Xiamen Amoytop Biotech
Alternative Names: Ypeginterferon alfa-2aLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Xiamen Amoytop Biotech
- Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis B; Hepatitis C
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in China (SC, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in China (SC, Injection)
- 30 Jan 2012 Xiamen Amoytop Biotech completes a phase I trial in healthy volunteers in China (NCT01343186)